Maci

RSS

matrix-applied characterised autologous cultured chondrocytes

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Maci has expired following the marketing-authorisation holder’s decision not to pursue the renewal of the marketing authorisation.

This EPAR was last updated on 05/07/2018

Authorisation details

Product details
Name
Maci
Agency product number
EMEA/H/C/002522
Active substance
autologous cultured chondrocytes
International non-proprietary name (INN) or common name
matrix-applied characterised autologous cultured chondrocytes
Therapeutic area (MeSH)
Fractures, Cartilage
Anatomical therapeutic chemical (ATC) code
M09AX02
Publication details
Marketing-authorisation holder
Vericel Denmark ApS
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
27/06/2013
Contact address
Amaliegade 10,
DK-1256 Copenhagen K
Denmark

Product information

01/07/2018 Maci - EMEA/H/C/002522 - IAIN/0009

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other drugs for disorders of the musculo-skeletal system

Therapeutic indication

Repair of symptomatic cartilage defects of the knee.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
1 rating